AP4080A - Notch pathway signaling inhibitor compound - Google Patents

Notch pathway signaling inhibitor compound

Info

Publication number
AP4080A
AP4080A AP2014007362A AP2014007362A AP4080A AP 4080 A AP4080 A AP 4080A AP 2014007362 A AP2014007362 A AP 2014007362A AP 2014007362 A AP2014007362 A AP 2014007362A AP 4080 A AP4080 A AP 4080A
Authority
AP
ARIPO
Prior art keywords
inhibitor compound
signaling inhibitor
notch pathway
pathway signaling
notch
Prior art date
Application number
AP2014007362A
Other versions
AP2014007362A0 (en
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP2014007362A0 publication Critical patent/AP2014007362A0/en
Application granted granted Critical
Publication of AP4080A publication Critical patent/AP4080A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AP2014007362A 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound AP4080A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (2)

Publication Number Publication Date
AP2014007362A0 AP2014007362A0 (en) 2014-01-31
AP4080A true AP4080A (en) 2017-03-29

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007362A AP4080A (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Country Status (36)

Country Link
US (1) US8569286B2 (en)
EP (1) EP2736920B1 (en)
JP (1) JP6027110B2 (en)
KR (1) KR101578309B1 (en)
CN (1) CN103732612B (en)
AP (1) AP4080A (en)
AR (1) AR087107A1 (en)
AU (1) AU2012287251B2 (en)
BR (1) BR112014001600B1 (en)
CA (1) CA2841178C (en)
CL (1) CL2014000175A1 (en)
CO (1) CO6862159A2 (en)
CR (1) CR20140036A (en)
CY (1) CY1116645T1 (en)
DK (1) DK2736920T3 (en)
DO (1) DOP2014000011A (en)
EA (1) EA023044B1 (en)
EC (1) ECSP14013179A (en)
ES (1) ES2544937T3 (en)
GT (1) GT201400012A (en)
HR (1) HRP20150771T1 (en)
HU (1) HUE027534T2 (en)
IL (1) IL229988A (en)
JO (1) JO3148B1 (en)
MA (1) MA35611B1 (en)
ME (1) ME02171B (en)
MX (1) MX356536B (en)
MY (1) MY184303A (en)
PE (1) PE20141061A1 (en)
PH (1) PH12014500215B1 (en)
PL (1) PL2736920T3 (en)
PT (1) PT2736920E (en)
RS (1) RS54135B1 (en)
SI (1) SI2736920T1 (en)
TW (1) TWI568730B (en)
WO (1) WO2013016081A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
TWI704151B (en) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk inhibitors
TWI609687B (en) 2015-04-14 2018-01-01 美國禮來大藥廠 Targeted treatment of leiomyosarcoma
JO3491B1 (en) 2015-07-07 2020-07-05 Audion Therapeutics Compounds that inhibit NOTCH . pathway signaling
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
CN120661674A (en) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 Combination of LSD1 inhibitors for the treatment of solid tumors
AU2017249078B2 (en) * 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (en) * 2016-04-12 2025-03-12 Lilly Co Eli COMBINATION THERAPY WITH NOTCH AND PI3K/mTOR INHIBITORS.
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (en) * 2016-08-31 2019-04-02 伊莱利利公司 Dosage regimen for the treatment of solid tumors
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
HUE058802T2 (en) 2016-12-09 2022-09-28 Denali Therapeutics Inc Compounds suitable as RIPK1 inhibitors
CN110461335A (en) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 Combination therapy for the treatment of BCMA-related cancers and autoimmune disorders
KR102845789B1 (en) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 Chimeric antigen receptor and encoding polynucleotide specific for B cell maturation antigen
US12193994B2 (en) * 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2019266150A1 (en) * 2018-05-06 2021-01-07 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518481A (en) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
HRP20050663A2 (en) 2003-02-04 2006-12-31 F. Hoffmann - La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
AU2004270361B2 (en) 2003-09-09 2009-06-25 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
WO2005040126A1 (en) 2003-10-06 2005-05-06 F. Hoffman-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
KR101169628B1 (en) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 Malonamide derivatives as gamma secretase inhibitors
WO2008092786A1 (en) * 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
KR20100101624A (en) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 Use of a gamma-secretase inhibitor for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
EP2736920B1 (en) 2015-07-01
HRP20150771T1 (en) 2015-08-28
CN103732612A (en) 2014-04-16
KR101578309B1 (en) 2015-12-16
DOP2014000011A (en) 2014-07-31
BR112014001600B1 (en) 2022-09-13
JO3148B1 (en) 2017-09-20
US8569286B2 (en) 2013-10-29
CN103732612B (en) 2015-09-23
SI2736920T1 (en) 2015-08-31
MX2014001084A (en) 2014-02-27
PE20141061A1 (en) 2014-09-06
AR087107A1 (en) 2014-02-12
WO2013016081A1 (en) 2013-01-31
ME02171B (en) 2015-10-20
MX356536B (en) 2018-06-01
PL2736920T3 (en) 2015-11-30
ECSP14013179A (en) 2014-03-31
EA201490161A1 (en) 2014-04-30
AP2014007362A0 (en) 2014-01-31
RS54135B1 (en) 2015-12-31
AU2012287251A1 (en) 2014-01-30
CA2841178C (en) 2016-12-20
MY184303A (en) 2021-03-31
EP2736920A1 (en) 2014-06-04
CR20140036A (en) 2014-03-21
IL229988A (en) 2017-07-31
AU2012287251B2 (en) 2015-05-14
MA35611B1 (en) 2014-11-01
JP2014527042A (en) 2014-10-09
KR20140026624A (en) 2014-03-05
JP6027110B2 (en) 2016-11-16
HK1194086A1 (en) 2014-10-10
PH12014500215A1 (en) 2014-03-17
PH12014500215B1 (en) 2018-09-07
CA2841178A1 (en) 2013-01-31
NZ618891A (en) 2015-12-24
DK2736920T3 (en) 2015-07-20
CY1116645T1 (en) 2017-03-15
US20130029972A1 (en) 2013-01-31
GT201400012A (en) 2014-07-16
ES2544937T3 (en) 2015-09-07
TW201315732A (en) 2013-04-16
PT2736920E (en) 2015-09-16
TWI568730B (en) 2017-02-01
CO6862159A2 (en) 2014-02-10
HUE027534T2 (en) 2016-11-28
CL2014000175A1 (en) 2014-08-22
BR112014001600A2 (en) 2017-02-21
EA023044B1 (en) 2016-04-29

Similar Documents

Publication Publication Date Title
AP4080A (en) Notch pathway signaling inhibitor compound
IL265897A (en) Substituted imidazopyridinyl-aminopyridine compounds
ZA201400232B (en) Metalloenzyme inhibitor compounds
SMT201700596T1 (en) Inhibitor compounds
EP2723730A4 (en) Metalloenzyme inhibitor compounds
ZA201401553B (en) Cyclopropaneamine compound
ZA201408141B (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ZA201306580B (en) Cyclopropylamines as lsd1 inhibitors
PL2788343T3 (en) Metalloenzyme inhibitor compounds
GB201106817D0 (en) New compound
EP2708540A4 (en) Pyrimido-diazepinone compound
EP2751117A4 (en) Metalloenzyme inhibitor compounds
GB201211019D0 (en) Inhibitor compounds
GB201104669D0 (en) Compound
GB201108188D0 (en) Corrosion inhibitor
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201004308D0 (en) New inhibitor compounds
GB201100461D0 (en) Quenching compound
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound